VIVARUS
BIOPHARMA
Making a Difference: Changing Lives
We are an international pharmaceutical company focused on commercializing specialty pharmaceuticals for severe diseases.
Our focus is on specialty therapeutics that require a strong medical focus and excellent relationships with medical and scientific establishments.
Our founders successfully launched multiple therapies in Europe, US and Asia-Pacific for leading corporations such as Hoffmann-La Roche, Amgen, Alexion, Biogen and EUSA Pharma.
Through our unique approach, we secured market leadership for iconic brands such as Mabthera, Neulasta, Aranesp, Soliris, Qarziba and Sylvant.
We have completed successful pricing and reimbursement negotiations since 20 years in all European markets, Canada, Australia, South America and secured early access in France, Italy, Spain, Russia and Belgium.
What Makes Us Unique
We are parents, sons, daughters, brothers, sisters, and have personal experience of family with severe illnesses.
We are motivated by helping patients.
We want to be trusted ambassadors for the medical and scientific community.
Science and patient outcomes matter.
Creating a great working environment.
Treasure experience and embrace innovation.
Working every day towards being the best team, motivated by our purpose.
Live our values.
Delivering outstanding results.
The more suffering we see in patients the more we are motivated to go the extra mile.
Our Founders
Dr. Carsten Thiel PhD
Chief Executive Officer
Previously:
EUSA: CEO and Board
Alexion: EVP and CCO
Amgen: VP, Head of Europe
Roche: Global Business Lead / GM
Dr. Dev Kumar MD, JD and NED
Chief Legal Officer
Previously:
EUSA: GC, CCO, & CoSec
NWEH: NED
Biogen: Director UKI, Canada, MENA
BI: Head of Legal UKI
Testimonials & Awards
2010
“Best place to work award” in Germany
2018
Prix Galien Orphan Product Runner- Up (Qarziba)
2019
"European Deal of the Year" award at the LSX Life Stars awards
2019
Qarziba and Sylvant listed for fast-track approval in China by the NMPA via its Review and Approval Procedures for Urgently-Needed Pharmaceutical Drugs Developed Overseas
2020
Sunday Times Sage Tech Track 100 (fastest-growing sales)
2021
Entry in UK Parliament's 300 Years of Leadership & Innovation
2021
Sunday Times Sage Tech Track 100 (fastest-growing sales)
Our motivation is to help patients, who are in great need.
Our Values
Patient focus
Making a meaningful difference to people living with severe medical conditions, who have limited or no options for treatment. We place patients, their families, and carers at the centre of our mission.
Collaboration
Working together in connecting our expertise, patient insights, medical and scientific network, and innovative thinking to unhinge the full potential of our team.
Commitment
Engagement, perseverance, and dedication. We understand our duty to our patients.
Trust
Engage and rely on our relationships, driving every decision we make to ensure transparency, reliability, and unwavering commitment to team.
Partnering
With people and companies who share our values. Using the best scientists and third parties to deliver strong data and consistent quality, to deliver meaningful treatments to patients globally.
Product Launches
